Xellia Pharmaceuticals
Xellia is a leading producer and marketeer of fermented anti-infective APIs and injectable finished products.
Financials
Estimates*
| NOK | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 84.4m | 83.5m | 78.6m | 76.7m | 81.5m | 73.3m | 89.0m |
| % growth | - | (1 %) | (6 %) | (3 %) | 6 % | (10 %) | 21 % |
| Profit | 16.5m | 7.4m | 28.1m | 25.3m | 13.1m | 18.7m | 52.1m |
| % profit margin | 20 % | 9 % | 36 % | 33 % | 16 % | 25 % | 59 % |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$700m | Acquisition | ||
| Total Funding | - | ||
Recent News about Xellia Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.